Literature DB >> 19347725

The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas.

Semra Paydas1, Gulsah Seydaoglu, Melek Ergin, Seyda Erdogan, Sinan Yavuz.   

Abstract

Angiogenesis and lymphangiogensis are important in the proliferation and survival of the malignant hemeopoietic neoplasms. The aim of this study is to determine the prognostic role of angiogenesis and lymphangiogenesis in the development of lymphoma. For this aim, VEGF-A and VEGF-C were explored by immunohistochemistry in 177 cases. VEGF-C and VEGF-A were found to be positive in 34 and 61% of the samples. There was a good correlation between VEGF-C and VEGF-A expression (p = 0.0001). The clinical prognostic indicators were not significantly different between VEGF-C (+) and (-) and/or VEGF-A (+) and (-) cases. Overall survival (OS) rate was shorter in cases with VEGF-A (+) and VEGF-C (+) cases than with negative cases (p = 0.03 and p = 0.0005, respectively). The OS was significantly shorter in aggressive lymphomas expressing VEGF-A and VEGF-C but not in indolent lymphomas. The results of Cox regression analyses showed that VEGF-A and VEGF-C expressions are independent prognostic parameters (OR: 2.6, 95% CI: 1.3-5.0 for both (+) cases). In conclusion, VEGF-C and VEGF-A were positive in 34 and 61%, respectively, of the cases with NHL. The significant correlation between VEGF-C and VEGF-A suggests that lymphangiogenesis is important in the pathogenesis of lymphomas as shown in angiogenesis. The significantly shorter survival rates of VEGF-C and/or VEGF-A expressions indicate that angiogenesis and lymphangiogenesis are important in clinical outcome. Autocrine VEGF-A and VEGF-C crosstalks in lymphoma cells are important in lymphoma biology and inhibition of these signals with anti-angiogenic/anti-lymphangiogenic drugs and combination with chemo-immunotherapy regimens will be more useful in these cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347725     DOI: 10.1080/10428190802706665

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.

Authors:  Ranjana H Advani; Fangxin Hong; Sandra J Horning; Brad S Kahl; Judith Manola; Lode J Swinnen; Thomas M Habermann; Kristen Ganjoo
Journal:  Leuk Lymphoma       Date:  2011-12-05

2.  High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.

Authors:  Teresa M Cardesa-Salzmann; Luis Colomo; Gonzalo Gutierrez; Wing C Chan; Dennis Weisenburger; Fina Climent; Eva González-Barca; Santiago Mercadal; Leonor Arenillas; Sergio Serrano; Ray Tubbs; Jan Delabie; Randy D Gascoyne; Joseph M Connors; Jose L Mate; Lisa Rimsza; Rita Braziel; Andreas Rosenwald; Georg Lenz; George Wright; Elaine S Jaffe; Louis Staudt; Pedro Jares; Armando López-Guillermo; Elias Campo
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

3.  Lymphangiogenesis in non-Hodgkin's lymphoma and its correlation with cyclooxygenase-2 and vascular endothelial growth factor-C.

Authors:  Shu-Pei Ma; Mei Lin; Hai-Ning Liu; Jian-Xian Yu
Journal:  Oncol Lett       Date:  2012-07-23       Impact factor: 2.967

4.  R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.

Authors:  John F Seymour; Michael Pfreundschuh; Marek Trnĕný; Laurie H Sehn; John Catalano; Eva Csinady; Nicola Moore; Bertrand Coiffier
Journal:  Haematologica       Date:  2014-06-03       Impact factor: 9.941

Review 5.  VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.

Authors:  Jing Yang; Wenlu Li; Xin He; Guofei Zhang; Lan Yue; Ying Chai
Journal:  Dis Markers       Date:  2015-02-25       Impact factor: 3.434

6.  VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma.

Authors:  Tomasz Wróbel; Grzegorz Mazur; Justyna Dzietczenia; Katarzyna Gębura; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik
Journal:  Biomed Res Int       Date:  2013-08-26       Impact factor: 3.411

Review 7.  Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.

Authors:  Lutz Menzel; Uta E Höpken; Armin Rehm
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

8.  In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).

Authors:  Carlos Aya-Bonilla; Emily Camilleri; Larisa M Haupt; Rod Lea; Maher K Gandhi; Lyn R Griffiths
Journal:  BMC Genomics       Date:  2014-05-21       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.